Skip to content
Graphic of a grey and white triangle
Graphic of a grey and white triangle

Commercial Intellectual Property

Allen & Overy’s commercial intellectual property team advises clients on the full range of commercial contracts relating to the exploitation of IP rights.

With the ever-growing focus on innovation, protecting and leveraging IP assets is crucial. A&O’s commercial IP lawyers work closely with our M&A and antitrust colleagues to provide coordinated advice on the full range of IP-rich transactions.

We advise on complex cross-border collaborations, joint ventures and strategic licensing deals involving parties all over the world.

Our experience spans the most complex transactions and includes:

  • Licensing, joint ventures and collaborations
  • Sales and other forms of disposal of IP rights, including warranty protection
  • IP due diligence and verification, including related agreements
  • Antitrust risks in licensing, joint venture and non-compete arrangements, including related to the settlement of patent disputes
  • Procedures and negotiations of arrangements for parties seeking to exit, or in the event of insolvency or bankruptcy of one party
  • Distribution, agency, contract manufacture, supply, sponsorship and other commercial agreements
  • IP-backed asset financing and taking security interests over IP assets, including royalty monetisation agreements

Our experience

Marks & Spencer

Marks & Spencer

on the IP aspects of its GBP750m food delivery joint venture with Ocado, the UK’s leading pure play digital grocer.

Exscientia Limited

Exscientia Limited

on a research collaboration and licence agreement with Roche pursuant to which Exscientia will use its AI drug discovery platform to design pre-clinical drug candidates for Roche.

Colfax Corporation

Colfax Corporation

on the complex division and transfer of an existing trade mark portfolio, including WIPO and other foreign trade marks, in connection with its USD57m acquisition of ČKD Kompresory, based in Prague, Czech Republic, from ČKD Group.



on a licence agreement concerning several of its pharmaceutical cancer products with ONO, for several Asian territories.

News and insights

Blog Post: 20 November 2023

PREVAIL Act: Will Congress Succeed in Curtailing IPRs?

David Tennant and Colby Davis of our US IP litigation practice discuss whether the US Congress may limit the ways companies can effectively challenge the validity of US Patents through inter partes…

Read more
Propeller on a plane

News: 20 November 2023

Allen & Overy has advised MBDA UK Limited on its landmark GBP4 billion Polish air defence deal

Allen & Overy has advised MBDA UK Limited (MBDA) on its GBP4bn agreement with Polska Grupa Zbrojeniowa S.A., under which it will support PGZ’s delivery of the NAREW air defence programme for the…

Read more
Liquid dropping into test tubes in a laboratory

News: 21 September 2023

Allen & Overy has advised Exscientia on its USD674 million AI drug discovery collaboration with Merck KGaA

Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges.

Read more
Sky seen through high rise buildings

Publications: 01 February 2022

Soon there will be legal protection for whistleblowers. What are the employer’s obligations?

The Grand Duchy of Luxembourg has just tabled a bill aimed at transposing the European Directive on whistleblowers. Even if the bill has to go through the entire legislative process, and will most…

Read more

Recognition of our work

Related content